Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › ductal carcinoma in situ

Ductal carcinoma in situ

Part of Esophageal Adenocarcinoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for ductal carcinoma in situ

6 trials tracked for ductal carcinoma in situ.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 2 Other / NA 4
  1. Phase 2 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed
  2. Phase 2 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed
  3. N/A Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast Completed
  4. N/A Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed
  5. N/A Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ Completed
  6. N/A Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS) Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Evaluating Residual Disease and Upstaging Rates Following Vacuum-Assisted Breast Excision for DCIS
OB/GYN & Women's Health Meta-analysis
Evaluating Residual Disease and Upstaging Rates Following Vacuum-Assisted Breast Excision for DCIS High rates of residual disease found after vacuum-assisted breast excision
A meta-analysis of 5,302 patients reveals high rates of residual disease after VABE, highlighting specific predictors like nuclear grade.
A large analysis shows that about two-thirds of patients with DCIS still have residual disease after vacuum-assisted breast excision procedu…
Oct 2, 2026
PM-TRPV4 positivity associated with invasive progression in patients with ductal carcinoma in situ
Oncology Case-Control
PM-TRPV4 positivity associated with invasive progression in patients with ductal carcinoma in situ New Protein Test Predicts Which Breast Lesions Spread
This retrospective case-control study evaluated 44 patients with pure ductal carcinoma in situ (DCIS) to assess PM-TRPV4 status.
A new protein test on cell walls helps doctors predict which early breast changes might spread to invasive cancer.
medRxiv Apr 20, 2026